ANP32A Antibody [D12M13] | Primary Antibodies

Application: Reactivity: Rat, Mouse, Human

Usage Information

Dilution
WB1:2000-1:10000 IHC1:200-1:800 IF1:200-1:800

Application
WB, IHC, IF

Reactivity
Rat, Mouse, Human

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
29 kDa 29 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
ANP32A Antibody [D12M13 detects endogenous levels of total ANP32A protein.

Clone
D12M13

Synonym(s)
pp32, Leucine-rich acidic nuclear protein (LANP), Mapmodulin, PHAPI, ANP32A, C15orf1, LANP, MAPM, PHAP1

Background
ANP32A, also known as PHAP1 or acidic nuclear phosphoprotein 32 family member A, is a multifunctional member of the ANP32 family that regulates chromatin remodeling, phosphatase activity, apoptosis, and transcriptional control in both nuclear and cytoplasmic compartments. The protein contains an N-terminal leucine-rich repeat (LRR) domain that mediates protein-protein interactions and a highly acidic C-terminal tail enriched in aspartate and glutamate residues that interacts with histones and chromatin-associated factors. ANP32A functions as a component of the inhibitor of histone acetyltransferase (INHAT) complex, where it masks histone tails and suppresses histone acetyltransferase activity, thereby limiting chromatin relaxation and maintaining transcriptional repression at specific gene loci. ANP32A also modulates protein phosphatase 2A (PP2A) signaling through formation of inhibitory complexes involving SET and PP2A holoenzymes, reducing substrate dephosphorylation and sustaining phosphorylation of signaling proteins within MAPK and Akt pathways during stress and survival responses. Through PP2A regulation, ANP32A influences ERK, p38, and Akt signaling dynamics linked to proliferation, apoptosis resistance, and cellular adaptation. The protein additionally recruits HDAC3-containing repressor complexes to target promoters, contributing to histone deacetylation and chromatin condensation in proliferating cells. During apoptosis, ANP32A undergoes relocalization and caspase-3-mediated cleavage, generating fragments that participate in mitochondrial apoptotic signaling through interactions with Apaf-1 and regulation of Bak oligomerization and cytochrome c release. In neuronal systems, ANP32A contributes to PP2A-dependent tau dephosphorylation and maintenance of microtubule stability, linking its activity to neuronal integrity and cytoskeletal regulation. Altered ANP32A expression has been associated with several malignancies including prostate, breast, and pancreatic cancers, where disruption of PP2A regulatory balance and apoptotic signaling contributes to abnormal survival and tumor progression. ANP32A additionally serves as a host factor for influenza A virus polymerase complexes, supporting efficient viral RNA replication within the nucleus, while tissue-specific isoforms display variable phosphatase regulatory activity.

Background

ANP32A, also known as PHAP1 or acidic nuclear phosphoprotein 32 family member A, is a multifunctional member of the ANP32 family that regulates chromatin remodeling, phosphatase activity, apoptosis, and transcriptional control in both nuclear and cytoplasmic compartments. The protein contains an N-terminal leucine-rich repeat (LRR) domain that mediates protein-protein interactions and a highly acidic C-terminal tail enriched in aspartate and glutamate residues that interacts with histones and chromatin-associated factors. ANP32A functions as a component of the inhibitor of histone acetyltransferase (INHAT) complex, where it masks histone tails and suppresses histone acetyltransferase activity, thereby limiting chromatin relaxation and maintaining transcriptional repression at specific gene loci. ANP32A also modulates protein phosphatase 2A (PP2A) signaling through formation of inhibitory complexes involving SET and PP2A holoenzymes, reducing substrate dephosphorylation and sustaining phosphorylation of signaling proteins within MAPK and Akt pathways during stress and survival responses. Through PP2A regulation, ANP32A influences ERK, p38, and Akt signaling dynamics linked to proliferation, apoptosis resistance, and cellular adaptation. The protein additionally recruits HDAC3-containing repressor complexes to target promoters, contributing to histone deacetylation and chromatin condensation in proliferating cells. During apoptosis, ANP32A undergoes relocalization and caspase-3-mediated cleavage, generating fragments that participate in mitochondrial apoptotic signaling through interactions with Apaf-1 and regulation of Bak oligomerization and cytochrome c release. In neuronal systems, ANP32A contributes to PP2A-dependent tau dephosphorylation and maintenance of microtubule stability, linking its activity to neuronal integrity and cytoskeletal regulation. Altered ANP32A expression has been associated with several malignancies including prostate, breast, and pancreatic cancers, where disruption of PP2A regulatory balance and apoptotic signaling contributes to abnormal survival and tumor progression. ANP32A additionally serves as a host factor for influenza A virus polymerase complexes, supporting efficient viral RNA replication within the nucleus, while tissue-specific isoforms display variable phosphatase regulatory activity.

References
https://pubmed.ncbi.nlm.nih.gov/25156960/ https://pubmed.ncbi.nlm.nih.gov/26918356/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%